#United States #Salt Lake City #Sera Prognostics #Maternal Health #PreTRM Test

Sera Prognostics Financial Results and Strategic Development for 2025

Sera Prognostics Inc., known as The Pregnancy Company®, recently published its financial results for the fourth quarter and the entire year of 2025, marking a significant phase in the company's journey towards enhancing maternal and neonatal health. With a focus on innovative pregnancy biomarker information, Sera aims to provide valuable insights to doctors and patients, which is especially critical in preventing preterm births.

Key Highlights and Achievements

Among the remarkable achievements in 2025, the publication of the PRIME Study stands out. This landmark study demonstrated the efficacy of the PreTRM® blood test in significantly lowering the rates of preterm births and related complications. The findings indicate a remarkable 56% reduction in births before 32 weeks and a 32% drop before 35 weeks. Furthermore, the study revealed that fewer infants were admitted to intensive care units (NICUs), leading to improved health outcomes for newborns and substantial cost savings for healthcare systems.

In Europe, expert commentary on the PRIME Trial highlighted the PreTRM approach as a strategic fit within existing healthcare frameworks, which enhances the potential for widespread adoption across various markets.

Commercial Expansion and Strategies

Financially, Sera reported modest revenues of $10,000 in the fourth quarter of 2025, slightly lower than the $24,000 noted in the same period in 2024. However, the company's total revenue for the year reached $81,000, a marginal increase from $77,000 in 2024. Operating expenses for the quarter totaled $9 million, down from the previous year's $9.4 million, illustrating Sera's ongoing effort to manage costs while focusing on commercial activities.

Sera has expanded its commercial outreach across 13 states, engaging both commercial and Medicaid payers in discussions regarding the PreTRM program. With promising developments underway, the company aims to grow its market presence and enhance healthcare delivery, anticipating that the PRIME Study will catalyze increased demand for its services.

Leadership Enhancements

In a strategic move to bolster its leadership structure, Sera appointed several key figures in 2025. Dr. Tiffany Inglis took on the role of Chief Medical Officer, bringing years of relevant experience in women's health programs. Similarly, Lee Anderson was appointed as the Chief Commercial Officer, leveraging his extensive background in healthcare sales and marketing. These appointments will be critical as Sera transitions to a fully commercialized environment following the highlights of the PRIME Study.

Looking Ahead

Looking forward to 2026, Sera Prognostics is committed to transforming its initial validation success into broader adoption of the PreTRM Test. The focus will be on securing payer reimbursements and enhancing the company's influence in maternal and neonatal care.

With approximately $95.8 million in cash, cash equivalents, and securities on hand as of December 31, 2025, Sera is well-positioned to navigate the upcoming challenges of commercialization. This financial stability will enable the company to continue driving advancements in pregnancy care, with the goal of improving health outcomes for mothers and their newborns across the United States and beyond.

As Zhenya Lindgardt, the President and CEO, eloquently stated, 2025 marked a pivotal year for Sera, moving from clinical validation to commercial execution. With the groundwork laid, Sera is poised to make a measurable impact on the landscape of maternal health and significantly advance the companies' mission to enhance the quality of care for families across the nation.

For more information about Sera Prognostics and its innovative health solutions, visit Sera Prognostics' website.